Health-care companies rose as traders continued to buy back into obesity-drug makers.
Shares of Eli Lilly and Novo Nordisk rose by 4% or more amid renewed optimism about the sales prospects of the Glycagon-like peptide-1 class of weight-control drugs.
Big Pharma company Merck struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
08-09-24 1751ET
